CoChat

Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer

Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., Baselga, J. · 2005 · Journal of Clinical Oncology
Cited by 98

The DOI matches its Crossref record.

Abstract

564 Background: Temsirolimus (tem, CCI-779), a novel mTOR inhibitor, is well tolerated and has antitumor activity in heavily pretreated patients (pts) with metastatic breast cancer (MBC, Proc ASCO 22:193,2003). In this trial, we evaluate safety and activity of oral tem in combination with letrozole. Methods: Patients with measurable MBC were randomized in a 1:1:1 ratio (∼30 evaluable pts/arm): 1) letrozole alone or letrozole with 2) tem daily (tem daily arm) or 3) tem daily for 5 days every 2 weeks (tem intermittent arm). All pts received 2.5 mg letrozole daily. Results: Initially, tem doses were 25 mg daily and 75 mg intermittent but were amended to 10 mg daily and 30 mg intermittent because 10 of 12 pts had dose delays, reductions, or discontinuations. Data collected by 15 Nov 2004 are presented for the 92 pts enrolled after the amendment (tem daily: 33; tem intermittent: 30; letrozole alone: 29). Grade 1–4 toxicities, regardless of causality, that occurred in >30% of pts included 10 mg daily: asthenia (45%), mucositis (42%), peripheral edema (36%); 30 mg intermittent: asthenia (63%), mucositis (57%), arthralgia (37%), anorexia (37%), diarrhea (33%), epistaxis (33%); letrozole alone: asthenia (52%), nausea (31%). Grade 3–4 toxicities, regardless of causality, that occurred in >5% of pts included 10 mg daily: hyperglycemia (9%); 30 mg intermittent: hyperglycemia (17%), asthenia (7%), hypertension (7%), hypokalemia (7%); letrozole alone: none. Objective responses (RECIST) occurred, 10 mg daily: 9 PR; 30 mg intermittent: 1 CR, 8 PR; letrozole alone: 2 CR, 10 PR. Clinical benefit (CR + PR + SD ≥8 wks) was 82%, 83%, and 79%, respectively. Progressive disease occurred at ≤8 wks in 12%, 10%, and 14% of pts, respectively. Progression-free survival (PFS) at 1 yr was estimated to be 69%, 62%, and 48%, respectively. Median PFS has been reached for the letrozole alone arm (9.2 mo) but not for the combination arms. Conclusions: Letrozole with 10 mg daily or 30 mg intermittent temsirolimus showed tolerability and clinical activity. Early data suggest that PFS may be longer for the combination arms than for the letrozole alone arm. An actively recruiting phase 3 study is being conducted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth Wyeth Wyeth

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2005.23.16_suppl.564

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 98

Metadata

Authors
Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J.
Venue
Journal of Clinical Oncology
Published
2005-06
Volume
23
Issue
16_suppl
Pages
564-564
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2243880667
Cited by
98
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.564
The paper
Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J. (2005). Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.564

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.